Xenon Pharmaceuticals Receives "Buy" Rating and $55 Price Target from Chardan Capital

Xenon Pharmaceuticals (XENE) receives a "Buy" rating from Chardan Capital with a $55 price target. The analyst maintains the previous price target set on August 12, 2025, reflecting a consistent outlook. The company is a neuroscience-focused biopharmaceutical company advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.

Title: Xenon Pharmaceuticals (XENE) Maintains "Buy" Rating with $55 Price Target

Xenon Pharmaceuticals Inc. (XENE) has received a "Buy" rating from Chardan Capital, with the analyst maintaining a $55 price target. This rating and target price were set on August 12, 2025, and reflect a consistent outlook from the analyst [1]. Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. The company is advancing a novel product pipeline to address high unmet medical needs, including epilepsy and depression.

Xenon's product candidates include XEN1101, NBI-921352, and XEN496 for epilepsy, and Nav1.7 oral inhibitors for pain. The company's Phase 3 azetukalner X-TOLE2 FOS study patient recruitment is complete, with topline data anticipated in early 2026 [2]. Additionally, Phase 3 neuropsychiatric studies are underway with X-NOVA3 in MDD and X-CEED in BPD, and a Phase 1 healthy volunteer study for a lead Nav1.7 development candidate for pain has been initiated.

The company's shares were added to the Russell 3000 Growth Index and Russell 2000 Index, and RBC Capital Markets raised its price target on Xenon Pharmaceuticals to $57 from $55, maintaining an Outperform rating. Xenon presented at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 [2].

Based on the one-year price targets offered by 15 analysts, the average target price for Xenon Pharmaceuticals Inc (XENE) is $54.20, with a high estimate of $65.00 and a low estimate of $42.00. The average target implies an upside of 50.60% from the current price of $35.99 [1]. The consensus recommendation from 19 brokerage firms is "Outperform," indicating a favorable outlook for the company's stock.

Xenon Pharmaceuticals is well-positioned to capitalize on the rapidly evolving landscape of neurological therapeutics. The company's lead candidate, azetukalner, a novel Kv7 potassium channel opener, is advancing through late-stage clinical trials for focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), and major depressive disorder (MDD). With regulatory milestones on the horizon and a robust commercialization strategy in place, Xenon is positioned to capture significant market share in both epilepsy and depression treatment markets [3].

References
[1] https://www.gurufocus.com/news/3057019/xene-receives-buy-rating-and-55-price-target-from-chardan-capital-xene-stock-news
[2] https://www.ainvest.com/news/xenon-pharmaceuticals-q2-loss-widens-cfo-announced-2508/
[3] https://www.ainvest.com/news/xenon-pharmaceuticals-high-conviction-play-neurological-therapeutics-azetukalner-late-stage-development-2508/